Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seroquel Marketing Plan Included “Spinning The Data, aka Lilly”

This article was originally published in The Pink Sheet Daily

Executive Summary

Plantiffs attorneys allege that AstraZeneca internal documents reveal intense effort to imitate competitors, placate study investigators.

You may also be interested in...



Legal and Regulatory Round-up: TriCor Suit Settles, Seroquel Suits Are Tossed, FDA Opens New Post

Abbott settles TriCor antitrust suit with states: Abbott and its French marketing partner Fournier agreed to pay 24 states and the District of Columbia $22.5 million to settle a suit claiming they blocked generic competition for the cholesterol drug TriCor (fenofibrate) by making minor changes in the formulations to prevent generic substitutions. The 2008 suit also alleged that the companies filed baseless patent infringement suits against Teva and Impax to trigger a 30-month automatic stay of approval (1"The Pink Sheet," March 24, 2008). The Florida Attorney General's Office led the litigation. Last month Abbott settled its patent infringement suit against Teva, allowing Teva to begin marketing its generic fenofibrate in March 2011 (2"The Pink Sheet," Dec. 7, 2009). Direct purchasers had filed a similar TriCor antitrust suit against Abbott, which the company settled in 2008 for $184 million

Legal and Regulatory Round-up: TriCor Suit Settles, Seroquel Suits Are Tossed, FDA Opens New Post

Abbott settles TriCor antitrust suit with states: Abbott and its French marketing partner Fournier agreed to pay 24 states and the District of Columbia $22.5 million to settle a suit claiming they blocked generic competition for the cholesterol drug TriCor (fenofibrate) by making minor changes in the formulations to prevent generic substitutions. The 2008 suit also alleged that the companies filed baseless patent infringement suits against Teva and Impax to trigger a 30-month automatic stay of approval (1"The Pink Sheet," March 24, 2008). The Florida Attorney General's Office led the litigation. Last month Abbott settled its patent infringement suit against Teva, allowing Teva to begin marketing its generic fenofibrate in March 2011 (2"The Pink Sheet," Dec. 7, 2009). Direct purchasers had filed a similar TriCor antitrust suit against Abbott, which the company settled in 2008 for $184 million

Lesson from Lilly’s Zyprexa Settlement: Be Proactive In Monitoring Sales Reps

Companies might shield themselves from claims of off-label drug marketing by adopting oversight procedures mandated in Lilly's corporate integrity agreement with HHS

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel